LENZ THERAPEUTICS, INC. Restructuring Costs
LENZ THERAPEUTICS, INC. (LENZ) reported Restructuring Costs of $62.08 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. restructuring costs for the quarter ending 2023-12-31 was $10.95M.
- LENZ THERAPEUTICS, INC. restructuring costs for the quarter ending 2023-09-30 was $11.35M.
- LENZ THERAPEUTICS, INC. restructuring costs for the quarter ending 2023-06-30 was $37.20M.
- LENZ THERAPEUTICS, INC. restructuring costs for the quarter ending 2023-03-31 was $2.58M.
- LENZ THERAPEUTICS, INC. restructuring costs for fiscal 2023 was $62.08M.
- LENZ THERAPEUTICS, INC. restructuring costs for fiscal 2022 was $0.00.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $10.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $22.30M derived: sum of 2 quarters · filed 2024-02-27 | $59.50M derived: sum of 3 quarters · filed 2024-02-27 | $62.08M 10-K · filed 2024-02-27 |
| 2023-09-30 | $11.35M 10-Q · filed 2023-11-13 | $48.55M derived: sum of 2 quarters · filed 2023-11-13 | $51.13M 10-Q · filed 2023-11-13 | $51.13M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | $37.20M 10-Q · filed 2023-08-14 | $39.78M 10-Q · filed 2023-08-14 | $39.78M derived: sum of 3 quarters · filed 2024-02-27 | $39.78M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | $2.58M 10-Q · filed 2023-05-11 | $2.58M derived: sum of 2 quarters · filed 2024-02-27 | $2.58M derived: sum of 3 quarters · filed 2024-02-27 | $2.58M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 derived: sum of 3 quarters · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |